Form 4 for CHRS Coherus Oncology, Inc.
Accepted 2024-01-23 00:00:00 ET · period of report 2024-01-20 · accession 0001610717-24-000039 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-23 | 2024-01-20 | CHRS | Lanfear Dennis M | Pres, CEO, Dir | F - Tax | $2.44 | -11.2K | 708.7K | -2% | -$27.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-20 | F | D | 11,218 | $2.44 | 708,694 | D | — | — | (F1) Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction. |